MapLight Therapeutics, Inc. (MPLT) — Stock Score Summary

MapLight Therapeutics, Inc. (MPLT) has a MoatMap StockRank of 29/100 based on Quality (39/100), Value (36/100), and Momentum (41/100) factor scores. The current signal is SELL. MapLight Therapeutics is a clinical-stage neuroscience company. It lacks proven revenues, has high capital requirements, and is highly speculative, failing our fundamental quality and margin of safety requirements.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing novel therapeutics for central nervous system (CNS) disorders, with a primary focus on psychiatric and neurological conditions. The company employs a proprietary drug discovery platform to identify and advance differentiated small molecule candidates that target specific neuroreceptor pathways, aiming to address significant unmet medical needs with potential first-in-class treatments.

Key Financial Metrics

Price$29.27
Market Cap$1.4B
P/E (Forward)-7.03
Price/Book3.40
Return on Equity-81.0%
Return on Invested Capital-36.5%
Debt/Equity1.40
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-96M

MapLight Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is MapLight Therapeutics, Inc.’s (MPLT) StockRank?
MoatMap’s StockRank for MapLight Therapeutics, Inc. (MPLT) is 29/100, with a Sell signal. It is a composite of Quality (39), Value (36), and Momentum (41) factor ranks across MoatMap’s 19,000+ stock universe.
Does MapLight Therapeutics, Inc. have an economic moat?
MapLight Therapeutics, Inc. (MPLT) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is MapLight Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for MapLight Therapeutics, Inc. (MPLT) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is MapLight Therapeutics, Inc. in?
MapLight Therapeutics, Inc. (MPLT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksMPLT deep dive reportAI ChampionsHow we score stocksSense-check another stock